By Peter Orszag
Too much of the public discussion about the nation’s long-term fiscal imbalance is about Society Security, Medicare and Medicaid, in...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?
There's a lot of support for a federal comparative effectiveness agency, but would it actually curtail health care spending? The head of CBO says yes--when paired with the appropriate incentives.
By Peter Orszag
Too much of the public discussion about the nation’s long-term fiscal imbalance is about Society Security, Medicare and Medicaid, in...
Create an account to read this article
Already a subscriber?
Only Bausch Health’s Xifaxan may have had a lower initial offer among the 15 drugs in the current Medicare price negotiation round, researchers at the University of Washington and the University of California, San Diego, projected.
The proportion of AMNOG benefit assessments leading to a positive rating, which has a direct impact on drug pricing, has decreased in recent years, according to analysis from the VFA, the association representing the German pharmaceutical industry.
Pink Sheet reporter and editors discuss the FDA’s role in the Astra Zeneca Most Favored Nation drug pricing deal and the Justice Department interpreting the off-label promotion laws differently than the FDA.
The National Health Service said the roll out of ViiV Healthcare’s Apretude would bring England closer to its aim of becoming the first country in the world to end HIV transmissions by 2030.
Only Bausch Health’s Xifaxan may have had a lower initial offer among the 15 drugs in the current Medicare price negotiation round, researchers at the University of Washington and the University of California, San Diego, projected.
Sponsors should consider whether their TV commercials contain the same number of scene changes during the major statement as ads that received a violation letter.
One clear message from a US FDA listening session on leveraging knowledge across cell and gene therapy products is sponsors want more guidance on how the FDA’s new platform therapy pathway will function.